LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akcijų sąrašas・Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

492.82 1.27

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

491.57

Max

495.72

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-314M 1.7B
Pardavimai	-1.2B 11B
P/E Sektoriaus vid.	24.631 50.102
Pelnas, tenkantis vienai akcijai	5.44
Dividendų pajamingumas	0.39
Pelno marža	15.048
Darbuotojai	125,000
EBITDA	-905M 2.3B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+25.87% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.39% 2.33%
Kitas uždarbis	2026-07-22
Kitas dividendų mokėjimo data	2026-07-15
Kita Ex Dividend data	2026-06-15

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-29B 167B
Ankstesnė atidarymo kaina	491.55
Ankstesnė uždarymo kaina	492.82

Naujienos nuotaikos

By Acuity

35%

65%

96 / 344 reitingas Healthcare

Thermo Fisher Scientific Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 13:56; UTC

Uždarbis

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

2026-04-23 10:28; UTC

Uždarbis

Thermo Fisher Posts Higher 1Q Profit, Revenue

2026-01-29 11:34; UTC

Uždarbis

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

2025-10-29 10:51; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

2025-10-23 20:49; UTC

Uždarbis

Correction to Thermo Fisher Article on Oct. 22

2025-10-22 10:28; UTC

Uždarbis

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

2026-05-15 10:45; UTC

Rinkos pokalbiai

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

2026-04-23 10:01; UTC

Uždarbis

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

2026-04-23 10:01; UTC

Uždarbis

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

2026-04-23 10:00; UTC

Uždarbis

Thermo Fisher 1Q Net $1.65B >TMO

2026-04-23 10:00; UTC

Uždarbis

Thermo Fisher 1Q Adj EPS $5.44 >TMO

2026-04-23 10:00; UTC

Uždarbis

Thermo Fisher 1Q EPS $4.43 >TMO

2026-04-23 10:00; UTC

Uždarbis

Thermo Fisher 1Q Rev $11.01B >TMO

2026-03-24 12:04; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

2026-03-24 12:00; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

2026-01-29 11:01; UTC

Uždarbis

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

2026-01-29 11:00; UTC

Uždarbis

Thermo Fisher: Entering 2026 From Position of Strength >TMO

2026-01-29 11:00; UTC

Uždarbis

Thermo Fisher 4Q Net $1.96B >TMO

2026-01-29 11:00; UTC

Uždarbis

Thermo Fisher 4Q Rev $12.22B >TMO

2026-01-29 11:00; UTC

Uždarbis

Thermo Fisher 4Q EPS $5.21 >TMO

2026-01-29 11:00; UTC

Uždarbis

Thermo Fisher 4Q Adj EPS $6.57 >TMO

2025-10-29 10:06; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

2025-10-29 10:05; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

2025-10-29 10:05; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

2025-10-29 10:04; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

2025-10-29 10:00; UTC

Įsigijimai, susijungimai, perėmimai

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

2025-10-22 10:01; UTC

Uždarbis

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

2025-10-22 10:00; UTC

Uždarbis

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

2025-10-22 10:00; UTC

Uždarbis

Thermo Fisher 3Q Adj EPS $5.79 >TMO

2025-10-22 10:00; UTC

Uždarbis

Thermo Fisher 3Q Rev $11.12B >TMO

Akcijų palyginimas

Kainos pokytis

Thermo Fisher Scientific Inc Prognozė

Kainos tikslas

By TipRanks

25.87% į viršų

12 mėnesių prognozė

Vidutinis 613.27 USD 25.87%

Aukščiausias 685 USD

Žemiausias 490 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Thermo Fisher Scientific Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

Pirkti

Laikyti

Parduoti

Remiantis 18 analitikų, pateikusių Thermo Fisher Scientific Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

96 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar